GlassScriptPhysician profile
Susan Butler-Sumner
NPI 1205896305
$12,039.40
in general payments reported to CMS, 2019-2025
40 companies · $1,641 in 2025
The $1,641 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $549 · 2020: $2,411 · 2021: $2,827 · 2022: $2,054 · 2023: $1,148 · 2024: $1,409 · 2025: $1,641.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,198.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $1,946.85 | 2020-2021 | |
| Abbvie INC. | $1,923.01 | 2019-2025 | Vraylar, Qulipta, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $1,490.15 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $1,330.73 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $740.05 | 2020-2025 | Wegovy, Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $642.61 | 2021-2023 | |
| Lilly USA, LLC | $444.03 | 2020-2023 | Mounjaro |
| Axsome Therapeutics, INC. | $378.95 | 2023-2025 | Auvelity, Symbravo |
| Sanofi-Aventis U.S. LLC | $364.77 | 2020-2022 | |
| Amgen INC. | $355.40 | 2019-2025 | Repatha, Otezla, Otezla |
| Allergan, INC. | $282.51 | 2020 | |
| Phathom Pharmaceuticals, INC. | $257.04 | 2024-2025 | Voquezna |
| Kowa Pharmaceuticals America, INC. | $178.72 | 2021-2023 | Livalo, Seglentis |
| Mylan Specialty L.P. | $158.96 | 2019-2023 | Yupelri |
| Esperion Therapeutics, INC. | $142.19 | 2020-2021 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Butler-Sumner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.